VistaGen Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shawn K. Singh
- Full Time Employees
- 41
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 343 Allerton Avenue South San Francisco CA United States of America 94080
- IPO Date
- Jun 21, 2011
- CIK
- 0001411685
- Website
- vistagen.com
- Similar Companies
- Business
- VistaGen Therapeutics, Inc. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience-based therapies via nose-to-brain neurocircuitry, develops and seeks to commercialize intranasal pherine product candidates for neuropsychiatric and neurological disorders. The company's diversified pipeline features fasedienol (PH94B), an investigational pherine nasal spray in Phase 3 PALISADE-3 and PALISADE-4 trials for acute treatment of anxiety in adults with social anxiety disorder; itruvone (PH10), an odorless synthetic investigational neuroactive pherine nasal spray in Phase 2 trials for major depressive disorder; PH80, an investigational pherine nasal spray in Phase 2 for vasomotor symptoms including menopausal hot flashes and premenstrual dysphoric disorder; PH15, an investigational pherine nasal spray in Phase 2 for cognitive impairment due to mental fatigue; PH284, an investigational pherine nasal spray in Phase 2 for loss of appetite and cachexia associated with chronic disorders such as cancer or heart disease; and AV-101, an oral NMDA receptor prodrug targeting depression, suicidal ideation, and neuropathic pain. Founded in 1998 and headquartered in South San Francisco, California, VistaGen Therapeutics operates primarily in the United States with a focus on patients suffering from psychiatric conditions including social anxiety disorder, depression, and women's health disorders related to menopause. Recent developments include completion of the randomized portion of the PALISADE-3 Phase 3 trial with topline results expected in Q4 2025 and PALISADE-4 topline results anticipated in H1 2026; appointment of Paul Edick, former CEO of Xeris Pharmaceuticals, to the Board of Directors in October 2025; appointment of Elissa Cote as Chief Corporate Development Officer; presentation of new PH80 data at The Menopause Society 2025 Annual Meeting; fiscal 2026 Q2 results showing $77.2 million in cash equivalents as of September 30, 2025 amid increased R&D spending of $15.9 million; and ongoing open-label extension in PALISADE-3 allowing fasedienol use for up to 12 months.
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average – Should You Sell?
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Above 50-Day Moving Average – Here’s Why
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm